Some 65% of Organizations Now Weigh Their Cyber Maturity
New ISACA survey data also shows a 35% increase in cyberattacks over the past year.
Steve Zurier
PDF
For many organizations it s no longer just about assessing cyber risk, but also the maturity of their cybersecurity programs.
Some 80% of organizations see value in conducting a cyber-risk assessment, while 65% go a step further and assess their cyber maturity, according to the newly released ISACA State of Cybersecurity 2021 report Part 2.
Enterprises performing these assessments are more likely to have sufficiently staffed security teams and are also more likely to have well-funded cybersecurity budgets, the report shows. And respondents with a pulse on security-program measurement and maturity are more than two times more confident in the ability of their enterprise to detect and respond to cyberattacks.
Most businesses sidestepped security processes during pandemic
itproportal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itproportal.com Daily Mail and Mail on Sunday newspapers.
The Network: The Washington Post s regular survey of cybersecurity experts
washingtonpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from washingtonpost.com Daily Mail and Mail on Sunday newspapers.
Shares of
PTC Therapeutics, Inc. (NASDAQ:PTCT) has price volatility of 9.66% in last 5 days trading session, while shares of firm closed at $14.29 jumping up 10.35% in last session. PTC Therapeutics (PTCT) expected to report Translarna revs of $81 million in 2016; provides clinical update. The firm provides a corporate update, which will be detailed at its presentation at the JP Morgan Healthcare Conference on Wednesday. The firm expects to report Translarna (ataluren) sales for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) of approximately $81 million for 2016, an increase of 140% and achieving the upper-end of guidance. This strong performance reflects rapid uptake, sustainable pricing, and high (>90%) compliance to treatment. For 2017, co expects to achieve ex-U.S. TranslarnanmDMD sales of $105-125 million. This is driven by both surged penetration into the over 25 countries where Translarna is currently accessible as well as continued geographic expan